Horizon Pharma Inc. (HZNP) Receives “Buy” Rating from Mizuho
A number of other equities analysts have also recently weighed in on the stock. Stifel Nicolaus reissued a buy rating and issued a $45.00 price objective on shares of Horizon Pharma in a research report on Wednesday, July 6th. Goldman Sachs Group Inc. reissued a buy rating and issued a $27.00 price objective on shares of Horizon Pharma in a research report on Tuesday. Brean Capital reissued a buy rating and issued a $30.00 price objective on shares of Horizon Pharma in a research report on Thursday, July 14th. Zacks Investment Research cut shares of Horizon Pharma from a buy rating to a hold rating in a research report on Thursday, August 11th. Finally, Jefferies Group reissued a buy rating on shares of Horizon Pharma in a research report on Thursday, September 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Horizon Pharma currently has an average rating of Buy and an average price target of $30.00.
Horizon Pharma (NASDAQ:HZNP) traded up 2.31% on Thursday, reaching $18.18. The company had a trading volume of 716,655 shares. The stock’s 50-day moving average price is $19.86 and its 200 day moving average price is $17.66. Horizon Pharma has a 52-week low of $12.86 and a 52-week high of $23.70. The firm’s market capitalization is $2.93 billion.
Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.12. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The firm earned $257.40 million during the quarter, compared to the consensus estimate of $235.43 million. During the same period in the prior year, the firm earned $0.39 EPS. The firm’s quarterly revenue was up 48.9% compared to the same quarter last year. On average, equities analysts anticipate that Horizon Pharma will post $2.15 earnings per share for the current fiscal year.
In related news, EVP Jeffrey W. Sherman sold 2,900 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total value of $58,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.10% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. BlackRock Fund Advisors raised its position in Horizon Pharma by 127.3% in the second quarter. BlackRock Fund Advisors now owns 6,678,136 shares of the biopharmaceutical company’s stock worth $109,989,000 after buying an additional 3,740,449 shares in the last quarter. State Street Corp raised its position in Horizon Pharma by 149.1% in the second quarter. State Street Corp now owns 4,201,164 shares of the biopharmaceutical company’s stock worth $69,194,000 after buying an additional 2,514,430 shares in the last quarter. Deerfield Management Co. raised its position in Horizon Pharma by 17.6% in the first quarter. Deerfield Management Co. now owns 13,740,261 shares of the biopharmaceutical company’s stock worth $227,676,000 after buying an additional 2,055,460 shares in the last quarter. Fiera Capital Corp purchased a new position in Horizon Pharma during the second quarter worth approximately $28,892,000. Finally, BlackRock Institutional Trust Company N.A. raised its position in Horizon Pharma by 57.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 3,673,204 shares of the biopharmaceutical company’s stock worth $60,498,000 after buying an additional 1,335,251 shares in the last quarter. 85.25% of the stock is owned by hedge funds and other institutional investors.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Stock Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related stocks with our FREE daily email newsletter.